Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_2817_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •The Nervous System
- •The Nervous System
- •ACKNOWLEDGEMENTS
- •SERIES EDITOR FOREWORD
- •PREFACE
- •CONTENTS
- •Introduction
- •Gross anatomy of the spinal cord and vertebral column
- •Spinal cord cell types
- •Receptive fields
- •Somatosensory pathways
- •The discriminative touch system
- •The ventrolateral system: pain and temperature
- •Spinoreticular tract
- •Spinotectal tract
- •The proprioceptive system
- •Functional organization of the spinal cord
- •Summary of somatosensory pathways
- •Blood supply to the spinal cord
- •Damage to the spinal cord
- •Imaging the spinal cord
- •Pathophysiology of spinal cord injury
- •Spinal cord syndromes
- •Complete cord transection
- •Spinal cord hemisection (Brown–Séquard syndrome)
- •Anterior cord syndrome
- •Amyotrophic lateral sclerosis
- •Infective diseases: poliomyelitis and syphilis
- •Syringomyelia
- •Management of spinal cord injury and future therapies
- •Comments on the case history
- •Introduction
- •Internal organization of the brainstem
- •Reticular formation
- •Principal functions of the RF
- •Mediating behavioural responses: arousal, alertness and affect
- •Modulating pain perception
- •Modulating spinal and cranial motor functions (muscle tone, reflexes and body posture)
- •Coordinating motor survival (autonomic) centres
- •Blood supply to the brainstem
- •Brainstem reflexes
- •Pupillary light reflex
- •Accommodation reflex
- •Gag reflex
- •Jaw jerk reflex
- •Blink reflexes
- •Brainstem lesions
- •Comments on the case history
- •Introduction
- •Physiological control of cerebral blood flow
- •Blood supply to the brain
- •Main terminal branches of the anterior system
- •Main terminal branches of the posterior system
- •Venous system
- •Functional anatomy of the cerebral vasculature
- •Angiography
- •Stroke
- •Classification of stroke
- •Mechanisms of cell injury in ischaemic stroke
- •Rehabilitation of stroke patients
- •Prognosis for recovery
- •Head injury
- •Focal pathology in relation to vascular injury
- •Skull fractures
- •Meninges
- •Extradural haemorrhage
- •Subdural haemorrhage
- •Subarachnoid haemorrhage
- •Brain contusions and lacerations
- •Intracerebral (parenchymal) haemorrhage
- •Diffuse pathology
- •Concussion and chronic traumatic encephalopathy
- •Treatment of head injury
- •Comments on the case history
- •Introduction
- •Types of infection of the central nervous system
- •The meninges
- •Dura mater
- •Arachnoid mater
- •Pia mater
- •Cerebrospinal fluid production and circulation
- •The blood–brain barrier
- •Meningitis
- •Bacterial meningitis
- •Aseptic and viral meningitis
- •Diagnosis and treatment of meningitis
- •Treatment of meningitis
- •Encephalitis
- •Cerebral abscesses
- •Brain infections in the immunocompromised patient
- •Introduction
- •Classification of mood disorders
- •Clinical features of mood disorders
- •Non-pharmacological management
- •Electroconvulsive therapy
- •Other stimulation therapies
- •Psychotherapy
- •Bipolar disorder and its treatment
- •General comments on mood disorders
- •Treatment resistance in depression
- •Need for new therapeutic targets
- •Comments on case history
- •Anxiety disorders
- •Genetics of mood disorders
- •Neurobiology of depression
- •Structures involved
- •Neurochemistry
- •Treatment of depression
- •Pharmacological management
- •Treatment of anxiety disorders
- •Insomnia
- •Introduction
- •Addiction and drug misuse: general comments
- •Neurobiology of addiction
- •Opiates
- •Cocaine and crack
- •Cannabis
- •Nicotine
- •Alcohol
- •Phencyclidine
- •Amphetamines
- •Methylenedioxymethamphetamine—‘Ecstasy’
- •Hallucinogens
- •Solvents
- •Addiction and rehabilitation: general comments
- •Index

17
the effects of stopping intake were well known: after the
rush of energy and euphoric state, and the decreased
need to sleep or eat, the users would experience a ‘crash’,
dominated by tiredness and depression. Typically, this
would lead to further drug intake. The only amphetamines currently used for medical purposes are dexamphetamine for narcolepsy and methylphenidate (an
amphetamine- related compound) for the treatment of
hyperactive children suffering from attention- deficit/
hyperactivity disorder.
Amphetamines can be snorted, taken orally or
injected. After heroin, amphetamine is the most abused
injected drug in the UK. There is particular concern
over the use of methamphetamine, which is stronger
than amphetamine and causes an intense and longerlasting ‘high’. Its chronic use can lead to strong psychological dependence and bouts of intense depression
after the ‘high’. In 2020 it was estimated that there were
7.4 million dependent amphetamine users worldwide.
Dependence on amphetamine/methamphetamine is
associated with depression, psychosis, anxiety and cardiovascular disease.
Amphetamine overdose can lead to cardiac arrhythmia, paranoid ideation, hyperactivity and hyperthermia.
Paranoia may be accompanied by hallucinations, and
it is known that amphetamine ingestion can precipitate
relapse in schizophrenic patients. The combination of
hyperthermia and hyperactivity may lead to an acidotic
state, convulsions and death. Intense headache and dyskinesias may also occur. The management of amphetamine overdose relies on the use of benzodiazepines
and antipsychotics. In the latter category, drugs with an
α- adrenergic component are preferred, such as chlorpromazine, in order to counter the increased sympathetic
activity. Since amphetamine is a base that is excreted
unchanged in the urine, it is possible to acidify urine
with ammonium chloride and thus significantly increase
the rate of excretion.
At present, there is no satisfactory treatment for addiction to amphetamines. A very wide range of treatments
have been explored so far, including antidepressant
drugs (e.g. mirtazapine), GABA agonists (e.g. baclofen),
partial nicotinic cholinergic agonists (varenicline), different stimulants (dexamphetamine and methylphenidate), glutamatergic agents (riluzole), opiate antagonists
(naltrexone) and CRF1 antagonists. However, the benefits shown are mild and inconsistent across studies.
Antipsychotic drugs and short- term benzodiazepines can
be used for the management of acute withdrawal symptoms. Psychosocial interventions that have shown some
benefits include cognitive behavioural therapy and contingency management.
Methylenedioxymethamphetamine—‘Ecstasy’
One of the most abused recreational drugs is a substituted
amphetamine: 3,4- methylenedioxymethamphetamine
(MDMA), also called ‘ecstasy’. MDMA is an amphetamine derivative structurally related to the hallucinogenic
compound mescaline. Since the mid- 1980s, MDMA has
become a very popular recreational drug associated with
live music venues, especially ‘rave’ parties. Ecstasy tablets come in a variety of shapes, sizes and colours. Doses
and purity vary widely. A 2012 Dutch study found that
the occurrence of significant adverse events after ecstasy
use, for example, palpitations, agitation, hyperthermia
and seizures, were attributed to the presence of contaminants such as methylenedioxyamphetamine and metachlorophenylpiperazine. The effects of the drug occur
after a latent period of 20–60 min and may last for 3–6 h.
MDMA users report a state of relaxation and euphoria.
The drug appears to increase empathy and to sharpen
emotions. It decreases inhibitions and heightens the perception of sounds and colours.
The case history illustrates the dangers associated
with the use of this drug and the misperception that
it is rather mild and innocuous. According to the 2014
United Nations World Drug Report, Australia ranks as
the highest per capita consumer of the drug. Most hospital admissions and, ultimately, deaths associated with
this drug are the result of hyperthermia, which leads to
breakdown of skeletal muscle (rhabdomyolysis), and
associated multiple organ failure. Furthermore, ingestion of large volumes of water in an attempt to decrease
the effects of hyperthermia and dehydration (due to
many hours of dancing, for example) may lead to a typical hyponatraemic syndrome, exacerbated by increased
secretion of anti-diuretic hormone. The retention of
water leads to dilution of the extracellular medium. The
subsequent brain swelling is accompanied by signs of
increased intracranial pressure. Death may occur as a
result of brain herniation. The case history illustrates a
typical toxic ecstasy syndrome, which luckily resolved
within 48 h but which may have also ended in the death
of the young person involved. Young women are particularly sensitive to the toxic effects of ecstasy. In the case
history the restoration of a normal Na+ level was probably crucial in saving the life of the patient.
There is increasing concern that the use of ecstasy
leads to irreversible brain structural changes. The pharmacodynamic profile of this drug is complex. The acute
administration of MDMA leads to increased release of
5- HT in the brain. This effect involves an interaction with
the 5- HT reuptake system. MDMA also inhibits MAO
activity (with a 10-fold higher potency at MAOA than at
MAOB). The drug can also increase dopamine release but
its effects may not involve the dopamine transport system; instead, diffusion into the dopaminergic terminal
followed by displacement of dopamine from vesicles.
Finally, MDMA can also acutely increase the release of
noradrenaline. MDMA binds to a variety of receptors; it
shows high affinity for 5- HT2, α2- adrenergic, M1 muscarinic and H1 histamine receptors, and lower affinity for
5- HT1, β- adrenergic and α1- adrenergic receptors.
Research in monkeys has shown that MDMA has a
neurotoxic effect on the 5- HT innervation of the forebrain
(see Fig. 17.7). The loss of 5- HT fibres may be partly
reversible in some brain structures, but it is question-
ADDICTION
369THE NERVOUS SYSTEM

17
ADDICTION
a
b
Fig. 17.7 Neurotoxicity of MDMA in monkeys exposed semiacutely to the drug. (a) Dark- field photomicrograph showing
5- hydroxytryptamine (5- HT) fibres in the caudate nucleus (A) in control
animals, (B) 2 weeks after a 3- day exposure to MDMA, and (C) 7 years
after a 3- day exposure to MDMA. (b) Dark- field photomicrographs
showing 5- HT fibres in the hippocampus (A) in control animals, (B)
2 weeks after a 3- day exposure to MDMA, and (C) 7 years after
a 3- day exposure to MDMA. H, Hilus; M, the molecular layer; O,
stratum oriens; P, stratum pyramidale; R, stratum radiatum. (From
Hatzidimitriou et al. (1999). Journal of Neuroscience 19:5096–107.)
able whether full recovery ever occurs. As illustrated
in Fig. 17.7, the effects are spectacularly long lasting.
Thus, after only three administrations of ecstasy, 7 years
before their brain tissue was analysed, the monkeys still
showed significantly decreased serotonergic innervation
of the striatum and of the hippocampus. Positron emission tomography (PET) studies in chronic ecstasy users
confirm that serotonin transmission is altered, raising
the possibility that the regular use of ecstasy in humans
irreversibly affects serotonergic signalling. Furthermore,
it has been shown that long- term use of recreational
MDMA leads to discrete changes in brain glucose metabolism, which can be correlated with specific verbal memory deficits.
Hallucinogens
Drugs that induce mental changes similar to psychotic
states are called hallucinogens or ‘psychedelic’ drugs. In
1938 the Swiss chemist Albert Hofmann synthesized the
compound lysergic acid diethylamide (LSD) and a few
years after its synthesis accidentally ingested some powder, subsequently experiencing the ‘mind- expanding’
properties of this compound. The effects (also known as
‘the trip’) were described as a ‘dream- like state’ during
which sensory modalities fused. Hallucinations during
which sensory modalities are mixed up are called ‘syn-
esthetic’. Interestingly, such hallucinations are sometimes
encountered in patients with temporal lobe epilepsy. The
sense of time is disrupted but memory is unaffected.
Feelings of total detachment and depersonalization may
occur. Hallucinogens may affect mood, but the type of
effect seen is context- dependent and depends on the
mindset of the user. Good ‘trips’ as well as terrifying,
bad ‘trips’ can be experienced by the same user. There
is increased sympathetic activity, with increased blood
pressure and pulse rate, dilated pupils and increased
body temperature.
The structure of LSD and other hallucinogens, such
as the compounds extracted from the psilocybe mushroom (i.e. psilocybin) or the peyote cactus (i.e. mescalin),
are very similar to that of serotonin. It is now well established that LSD can activate presynaptic 5- HT receptors, and thus decrease the activity of raphe serotonergic
neurons. This may underlie, at least partly, the effects
of the hallucinogen, but the compound has a complex
pharmacology, involving several types of 5- HT receptor.
LSD is a very potent compound, with 25 µg being sufficient to induce hallucinations. Death from LSD overdose is rare, as the safety range of this compound is
wide. When overdose occurs, it manifests as vomiting,
respiratory arrest and coma. There is rapid tolerance to
the effects of LSD. Hallucinogens may lead to psychological but not physical dependence. Together with cannabis, ecstasy and amphetamine, LSD is among the most
popular drugs with club- goers. Experiencing the effects
of psychedelic compounds through ingestion of LSD or
‘magic mushrooms’ (its street name) is a common temptation among teenagers in particular, and some of the
self- reported effects and consequences are quite disturbing. Box 17.5 contains edited fragments of the comments
of two people who have eaten ‘magic mushrooms’.
An interesting development in the past 2–3 years
has been the new recognition of the potential therapeutic value of certain hallucinogens, such as psilocybin,
which could have unique therapeutic effects in depression and the management of addictions (e.g. alcohol and
tobacco). Like other psychedelic compounds, psilocybin exerts agonist effects at 5- HT2A receptors, which are
abundantly expressed on the large cortical pyramidal
cells. Magnetoencephalography and electroencephalography show that psilocybin induces an increase in cellular firing and, subsequently, desynchronized cortical
activity. This enhanced entropy effect leads to an increase
in cerebral connectivity patterns, possibly underlying
more insights into feelings, motives, beliefs and actions.
Notably, the regimen of treatment with these psychedelic agents is quite different from the usual regimens of
drug treatment in these conditions: for example, instead
of taking the drug daily, it is administered only on a
few occasions over several weeks, and it is used in conjunction with very structured psychotherapy support.
Overall, the proponents of this new ‘psychedelic psychiatry’, such as the scientists and clinicians at the newly
created Centre for Psychedelic Research, at Imperial
370 SYSTEMS OF THE BODY

17
Box
17.5
‘I had a terrible experience yesterday on mushrooms. I had
eaten them twice before with no problem… This time,
when I ate the 8th, I didn’t even finish them all. I felt fine
at first. We were going to go to the beach to “people
watch”. I got up to go to the bathroom first and all of a
sudden I felt extreme anxiety. I have never been so scared
in my life. I felt like I was fighting with myself. I started
screaming at my boyfriend. Everything I saw was changing and I didn’t know where I was. I was being really mean
to him one second and the next second I was apologizing,
trying to tell him I didn’t mean it. I could not understand
anything that was going on. I had no concept of anything.
Even time. I kept asking what time it was. Literally, a minute felt like it should have been 2 or 3 hours… He tried to
put on some soothing music and I made him take it out.
I couldn’t even watch commercials with music on television. Now, 24 hours later, I feel extremely sad and not quite
myself. I would appreciate it if you could … tell me what
happened. How can I get myself feeling normal again?’
experience. I became suicidal and for about 4 days I was
totally wasted. Today at the age of 47 I suffer from severe
depression and phobias and have had to have electroshock
treatment for a breakdown. Could this be related to that
bad experience all those years ago, and if so, what help
could I get, if there is a cure available?’
Going on ‘trips’
‘I took mushrooms at the age of 20 and had a very bad
College in London, suggest that these agents trigger a
profound and long- lasting beneficial neural plasticity.
Solvents
A wide variety of organic compounds that are used as
solvents, e.g. in paint, nail varnish remover and glue,
as well as cigarette lighter gas or propellant gas used in
aerosols, can be abused through inhalation (and so are
termed ‘inhalants’). Solvent abuse is commonly called
‘glue- sniffing’ and is a form of addiction that affects
mainly adolescents. It is quite common in the UK, and
it particularly affects young people in socially deprived
areas. These inhalants are rapidly absorbed and lead to
a sensation similar to that of being drunk. Irrespective of
their structures (i.e. aliphatic or aromatic hydrocarbons,
chlorinated hydrocarbons, acetates, ketones, ether or
chloroform), these agents initially produce a stimulating
effect, which is followed by depression. The molecular
targets activated by solvents to induce these effects are
not well defined. They include NMDA glutamate receptors, nicotinic cholinergic receptors, 5- HT3 receptors and
GABAA receptors. The effect is short- lived (usually a
few minutes) and repeat doses are required every hour.
The user can develop hallucinations and delusions and
may slip into a delirious state. Tolerance to solvents can
develop very quickly. There is no physical dependence
but there is strong psychological dependence. Chronic
exposure to solvents is likely to cause not only neurotoxicity but also hepatotoxicity and renal toxicity. Accidental
death can also be caused by suffocation or choking on
vomit after intense periods of sniffing that may trigger emesis. There is at present no treatment for solvent
abuse. Changes in legislation which restricts sales of
glues and solvents with high volatile organic compound
content are an example of a means of controlling this
type of addiction.
Addiction and rehabilitation: general comments
In the treatment of addiction there are three stages at
which interventions play an important role: (1) during
the active use of the drug, (2) to alleviate the symptoms
of withdrawal and (3) to prevent relapse. That addiction is a disease of the brain, with complex physical and
emotional aspects, is a relatively recent concept in the
history of medicine; some scholars have proposed different theories of addiction and question or reject the brain
disease model. For example, an alternative theory is that
addiction reflects a distorted deep learning process that
can be unlearned. Multiple drug addiction is a common
and significant societal problem. Addicts may use, at
the same time, varying combinations of alcohol, cocaine,
crack, methadone and PCP, and also sniff glue. Each of
these drugs, as discussed above, has its own characteristics and sometimes their negative effects can be synergistic. Cocaine and heroin can lead to tolerance. However,
under certain conditions, drugs of abuse such as amphetamine can lead to the opposite phenomenon, that of sensitization, that is, an enhancement of the effects of the
drug. Ethanol and opiates lead to physical dependence,
whereas cocaine and amphetamine much less so. Cues
associated with drug taking play a major role in relapse,
either a short time after abuse or after a long period of
abstinence. Thus, places, people or the paraphernalia
associated with drug abuse can trigger relapse. Stress
also appears to act as a triggering factor for relapse in
many addictions.
In parallel with the main substance use disorders
discussed in this chapter, another trend in society is the
emergence of new psychoactive substances, that is, drugs
designed to replicate the effects of substances like cannabis, cocaine and ‘ecstasy’ while remaining legal—hence
the alternative names: ‘legal highs’ or ‘designer drugs’.
They represent a heterogeneous class of substances,
known under various brand names, and include synthetic cannabinoids, psychostimulants, compounds with
sedative and anti-anxiety effects, and also substances
with hallucinogenic properties. These drugs are easily available online and are often adulterated with other
compounds. There is increasing evidence that demonstrates their short- term and long- term harm, in particular their strong addictive potential. The Psychoactive
Substances Act came into force in the UK in 2016, and
ADDICTION
371THE NERVOUS SYSTEM

17
it is illegal to produce, supply, or import these new substances for human consumption—including for personal
use.
The life of an addict can lead to extreme physical and
ADDICTION
moral degradation, as described by the autobiographies
or diaries of addicts: ‘I wake to the feeling of something
warm dripping down my chin. I lift my hand to feel my
face. My four front teeth are gone. I have a hole in my
cheek, my nose is broken and my eyes are swollen nearly
shut… I look at my clothes and my clothes are covered
with a colourful mixture of spit, snot, urine, vomit and
blood’. There are at present very few efficient ways of
treating addiction and, in the future, the answer may lie in
an approach based on a better understanding of the complex changes induced in the brain by chronic consumption
of drugs. Our present understanding of the neurobiology of addiction indicates that, in the brain of an addict,
homeostasis has been replaced by ‘allostasis’, that is, a
totally different set point, and efficiently treating addiction
will require better characterization of all the neurotransmitter and circuit changes involved in this allostatic transformation. What is also clear is that the life trajectory of
addicts and their substance misuse can be very different:
persistent use, declining use, cessation followed by relapse
or sustained cessation. There is a need for a better understanding of the factors that underlie this heterogeneity and
the development of reliable biomarkers of relapse, thus
leading to improved management of this significant and
life- changing brain condition.
Self- assessment case study
Alex recently graduated in engineering and was offered
a choice position to work on an oil platform in Scotland.
He has decided to celebrate with friends and go out for a
drink. He intends to make it a special occasion and drink
more than the usual few pints that he drinks almost
every night during the week. Whenever he is out with
his friends he has a reputation for ‘drinking everybody
under the table’. On the night of the celebration they start
the evening with a few whiskies and continue with beer.
After several hours of drinking, all of them are seriously
drunk. As they leave the pub, they attempt to cross the
road and Alex is hit by a car that he did not see. He suffers multiple fractures and is taken to the accident and
emergency department. The first 24 h in hospital seem to
go by in a haze and after the first day Alex starts to feel
very unwell, with alternating chills and sweating. During
the afternoon of the second day, he becomes aggressive
with the nurses and attempts to hit one of them. He also
claims that there are bugs in his bed ‘that crawl all over
him’. The doctor on duty decides to administer diazepam
and keep him under observation over the next 2–3 days.
After studying this chapter, you should be able to
answer the following questions:
1. What is Alex suffering from?
The symptoms that Alex is suffering from, taking
into account his history of alcohol consumption,
correspond to the development of a withdrawal
syndrome and a state of ‘delirium tremens’.
2. What are the main risks associated with the condition
that he develops in hospital?
A patient who develops symptoms of ‘delirium
tremens’ must be maintained under observation:
there may be onset of seizures, increased confusion
and psychotic episodes, and also autonomic
instability that will require appropriate management
before patient discharge.
3. What long- term treatment can you suggest in Alex’s
case?
After discharge from hospital, Alex would require
an assessment of his habit of consuming regularly
large quantities of alcohol. He is likely to have
developed alcohol use disorder, which could be
managed using a combination of pharmacological
and non-pharmacological strategies.
372 SYSTEMS OF THE BODY

Index
Note: Page numbers followed by ‘f’ indicate figures, ‘t’ indicate tables and ‘b’ indicate box.
A
Abducens nerve. See Cranial nerve VI
(abducens nerve)
Abnormal ideas, schizophrenia, 319
Abnormal perceptions, schizophrenia,
319
Absence seizures, 280, 282
Absolute refractory period, 42
Acamprosate, alcohol dependence
treatment, 368
Accessory nerve. See Cranial nerve XI
(accessory nerve)
Accommodation reflex. See Visual system
ACE inhibitors, stroke prevention, 241–242
Acetaminophen (paracetamol), 110
Acetylcholine (ACh), 180
inactivation, 51
as neurotransmitter, 45–46
skeletal muscle contraction, 179–182
Acetylcholinesterase (AChE)
Alzheimer’s disease, 309–310
skeletal muscle contraction, 179–182
ACh. See Acetylcholine (ACh)
AChE. See Acetylcholinesterase (AChE)
Acoustic neuromas, 168f
case history, 120b, 132–133
Action potentials, 41–42, 42f
absolute refractory period, 42
ion channels, 41–42
relative refractory period, 42
retinal ganglion cells, 139
sequence events, 43t
voltage- sensitive K+ channels, 42
voltage- sensitive Na+ channels, 42
Active zones, synaptic transmission, 41–42
Acupuncture analgesia, 99
Acute pain, 93, 93t
nociceptors, 93, 95, 101
non- steroidal anti- inflammatory drugs, 92
opioids, 92
Acyclovir, 269b, 271
Addiction, 356
benzodiazepines, 361
case history, 356b
definition, 356
drug classification, 358b
drug combination, 371
drugs of abuse, 358t
neurobiology, 357–371
physical degradation, 372
rehabilitation, 371–372
schizophrenia, 364–365
See also specific substances
Adduction defects, cranial nerve III, 56–57,
57f
Aδ fibres, nociceptors, 92
Adoption studies, mood disorders, 339
Advanced glycation products, Alzheimer’s
disease, 308
Affective flattening, schizophrenia, 320
Age of onset, depression, 338–339
Agitated depression, 334
Agoraphobia, 348t
Akinesia/bradykinesia, Parkinson’s disease,
205, 205f
Alcohol dependence, 366–368
central effects, 367
delirium tremens, 367–368
heritability, 367
Alcohol dependence (Continued)
neurotransmitters, 372.e1
peripheral effects, 367
pregnancy, 367
treatment, 367
Alexia, 154
Alpha rhythm, EEG, 278–280
Alteplase, stroke prevention, 241
Alzheimer’s disease, 302–308
β- amyloid hypothesis, 307
AGEs, 308
biomarkers, 305b
calcium homeostasis, 307
α- secretase, 305
protein structure, 305f
case history, 296b
CT, 298–299
diagnosis, 298–299
differential diagnosis, 314–315
elderly, 296
genetics, 303–304
amyloid precursor protein, 303
APOE gene, 302t, 303–304
presenilins, 303
MRI, 298–299
neuroinflammation, 308
C1q complement receptor, 308
microglia, 308
pathology, 304–307
choline acetyltransferase, 304
neuritic plaques, 304–306, 304f
neurofi brillary tangles, 306–307
neuronal degeneration, 306–307
neurotransmitters, 304
risk factors, 308, 310–311

INDEX
Alzheimer’s disease (Continued)
signs and symptoms, 361
tau pathology, 306–307
hyperphosphorylated tau, 306–307
microtubule bundling, 306–307
tubulin polymerization, 306–307
treatment, 308–312, 308t
amyloid peptide vaccines, 303–304
anti- amyloid strategies, 311–312
antioxidants, 310
anti-tau strategies, 312
cholinesterase inhibitors, 308–310
glutamatergic agents, 310
non- steroidal anti- inflammatory drugs,
310
risk factor reduction, 310–311
secretase inhibition, 311
tau pathology, 306–307
Amacrine cells. See Retina
Amantadine, Parkinson’s disease treatment,
213
American Spinal Injury Association (ASIA)
impairment scale, 80, 83t
Amnesia, 299
AMPA receptors, 300–301
antagonists, 308–309
epilepsy, 283–284
hippocampus LTP, 300
ischaemic stroke, 238–241
Amphetamines, 368–369
historical aspects, 368
overdoses, 369
Ampulla, 169, 170f
Amygdala, 16–17
connections, 16f
input, 17
learning, 301–302
aversive learning, 301–302
lesions, 14
sagittal plane, 5–6
β- Amyloid hypothesis. See Alzheimer ’s
disease
Amyloid peptide vaccines, Alzheimer’s
disease treatment, 303
Amyloid precursor protein, Alzheimer’s
disease, 306f
Amyotrophic lateral sclerosis (Lou Gehrig’s
disease), 84, 194
case history, 194
genetics, 194b
Analgesia, 78, 91
acupuncture analgesia, 99
arousal, 99
counter- stimulation, 97
non- nociceptive afferents, 97
opioid receptors and ligands, 99
See also specific drugs
supraspinal (descending), 97–99, 98f
brain regions, 97–98
direct postsynaptic inhibition, 98
direct presynaptic inhibition, 89
indirect inhibition, 98
locus coeruleus, 98
mechanisms, 99f
nucleus raphe magnus, 98, 98f
Analgesia (Continued)
periaqueductal gray, 113f
Analgesia flare, 101f
Anatomy/organization (of nervous system),
2–7, 6f
function relationship, 30
See also specific organs/structures
Aneurysms, haemorrhagic stroke, 64,
235–236
Angel dust. See Phencyclidine (PCP)
Angiography, 229
anterior circulation, 226f
clinical examination, 54
left common carotid artery, 232f
posterior circulation, 234f
Angiotensin II, hypothalamus, 22, 115
Angular gyrus, 166f
damage effects, 166b
Anhydrosis, autonomic nervous system
dysfunction, 29t
Animal models/studies
ecstasy, 369–370
epilepsy. See Epilepsy
Anopia, definition, 142t
Anoxia, ischaemic stroke, 238
ANS. See Autonomic nervous system (ANS)
Anterior cerebral artery (ACA), 226, 226f,
229f
functional anatomy, 231t
Anterior choroidal artery, 227
Anterior cord syndrome, 84
Anterior lobes
cerebellum, 194–200
lesions, 200
Anterior spinal arteries, 80
Anterior system branches, cerebral blood
flow, 227, 228f–229f
Anti- amyloid strategies, Alzheimer’s disease
treatment, 311
Anti- cholinergic agents, Parkinson’s disease
treatment, 213
Antibiotics
deafness, 168
meningitis treatment, 267–268
resistance, bacterial meningitis, 267b
Anticonvulsant drugs, 287–289, 346
efficacy, 288t
GABA level increase, 288–289, 290f
GABA receptor modulators, 288
meningitis treatment, 267–268
migraine prevention, 114b
neuropathic pain management, 111
See also specific drugs
side effects, 289
teratogenicity, 289
Antidepressant drugs
atypical, 343
classes, 342t
cocaine addiction treatment, 363
delayed effects, 346–347
monoamine reuptake effects, 343t
mood disorder therapy, 346–347
need for new therapeutic targets, 347
See also specific drugs
switching between, 347
Antidopaminergic agents, Huntington’s
disease, 220
Antioxidants, Alzheimer’s disease
treatment, 310
Antipsychotic drugs, 312–313, 327
amphetamine overdoses, 368–369
classification, 327t
pharmacodynamics, 328f
See also specific drugs
side effects, 328–329, 329t
neuroleptic malignant syndrome,
329–330
tardive dyskinesia, 330
Anti-tau strategies, 312
Anti-tau strategies, Alzheimer’s disease
treatment, 312
Anxiety disorders, 348–349, 348t
classification, 348t
See also specific disorders
treatment, 348–349
benzodiazepines, 349
APOE gene. See Alzheimer’s disease
Appearance, mental state examination,
55
Apraxias, 191b
cortical function examination, 61–62
Aqueous humour, 137, 137f
Arachnoid mater, 3, 23, 68, 247
spinal cord, 7
Arcuate fasciculus, damage effects, 166b
Argyll Robertson syndrome, pupil
asymmetry, 143t
Arousal analgesia, 99
Arteriovenous malformations, haemorrhagic
stroke, 236, 236f
Ascending pathways
auditory pathways, 163–164
brainstem, 122
defects, somatosensory pathways,
79f
Ascending reticular activating system
(ARAS), 93
Aseptic meningitis, 265, 267t
Asperger’s syndrome, 332
Aspirin, 110
atherosclerosis, 230
migraine treatment, 113–115
Association auditory cortex (AII), 165
Association nuclei, thalamus, 18–19
Astrocytes, 36–37, 38f
glial fibrillary acidic protein, 36–37
retina, 146–151
Asynchronous firing, motor
unit, 182
Asynergia, 199
Atherosclerosis, 230, 234f, 234b
aspirin, 234b
ATP- dependent Na+ pumps, ischaemic
stroke, 238
Audiometry
balance disorders, 158, 174–175
hearing tests, 167
Auditory and vestibular nerve. See Cranial
nerve VIII (auditory and vestibular
nerve)
374

Auditory brainstem response, hearing
tests, 167
Auditory encoding. See Auditory system
Auditory pathways, 163–164, 163f
ascending pathways, 163
bushy cells, 163
cochlear nerve afferents, 163
contralateral lateral lemniscus, 163
dorsal cochlear nucleus, 163
inferior colliculus, 163–164
intensity, 163
lateral lemniscus body, 163–164
location, 163, 163f
medial geniculate nucleus, 163
plasticity, 164b
stellate cells, 163
superior olivary nucleus, 163–164,
165f
trapezoid body, 163
ventral cochlear nucleus, 163
Auditory perception. See Auditory system
Auditory receptors. See Auditory system
Auditory system, 158–169
auditory encoding, 162
brainstem acoustic reflexes, 164–165
functions, 164b, 167
pathways. See Auditory pathways
perception, 162, 165
association auditory cortex, 165
functional imaging, 165
visual system vs., 163, 165
receptors, 160–162
hair cells, 160
inner hair cells, 160
organ of Corti, 160
outer hair cells, 160
See also Ear anatomy
sound transduction, 160–162
basilar membrane, 160, 161f
round window, 160–162, 167
Aura, migraine, 112
Auricle (outer ear), 159–160, 159f
Autism, 331
treatment, 331–332
Autonomic nervous system (ANS), 20–21,
25–30
dysfunction, 29–30, 29t
efferent output, 23–24
enteric system, 25–26
functional organization, 28f
neurotransmitters, 27–28
nicotine addiction, 363
parasympathetic division, 26–27
postganglionic neurones, 27
preganglionic neurones, 27
reflex circuitry, 25f
sympathetic division, 26
visceral sensations, 26–27
Autoregulation, cerebral blood flow, 225
Aversive learning, amygdala learning,
301–302
Axial plane, brain anatomy, 8f
Axons, 34–35
collaterals, 35
injury, 307
B
Babinski sign, 59, 79
Baclofen, trigeminal neuralgia management,
116
Bacterial meningitis, 263–265
antibiotic resistance, 267b
Haemophilus influenzae type b, 264
haemorrhagic rash, 263
Listeria monocytogenes, 264
Mycobacterium tuberculosis, 264
Neisseria meningitidis, 263
septicaemia, 263
Staphylococcus aureus, 264
Streptococcus pneumoniae, 263
Balance, 158
Balance disorders, 174–175
causes, 174
diagnosis, 175
audiometry, 175
caloric test, 175
Hallpike’s manoeuvre, 175
posturography, 175
See also specific diseases/disorders
treatment, 175
Barbiturates
insomnia therapy, 351
mood disorder therapy, 339
Barthel Index, 237–238
Basal ganglia, 202–204
anatomy, 8f, 14
circuits, 202–204
direct pathway, 203
functional organization, 203f
indirect pathway, 204
lesions, 20–21
movement control, 178
neurotransmitters, 202–204
GABA, 203
nucleus accumbens, 9
opioid receptors, 203
organization, 202–204
striatum, 202
structure, 202–204
Basilar membrane, sound transduction, 160,
161f
Basket neurones, cerebellum, 196
Behaviour, mental state examination, 55
Behavioural disorders, schizophrenia, 319–320
Benign paroxysmal positional vertigo
(BPPV), 174–175
Benserazide, L- DOPA combination, 210–211
Benzodiazepine receptors, insomnia therapy,
353b
Benzodiazepine(s)
abuse potential, 350
amphetamine overdoses, 368–369
anxiety disorder treatment, 349–351
complications in elderly, 351t
epilepsy treatment, 287–291
insomnia therapy, 351
mechanisms of action, 221.e1
pharmacokinetics, 287–288, 350–351, 351t
See also specific drugs
in sleep disturbances, 353
Berry aneurysms, haemorrhagic stroke,
235–236, 236f
β- blockers
cocaine addiction treatment, 363
migraine prevention, 114b
Bilateral signs, brainstem lesions, 131
Biofeedback, pain perception, 100, 349
Bipolar cells. See Retina
Bipolar disorder, 335–339, 345–346
genetics, 345
imaging, 345
lithium, 345
neuronal atrophy, 345
Bipolar neurons, 35, 36f
Bladder dysfunction, autonomic nervous
system dysfunction, 3
Blind spot, 139
Blindness
river blindness, 136
Blindsight, 154
Blink reflexes, brainstem, 130
Blood flow rate, 234b
Blood tests, dementia, 283, 298–299
Blood–brain barrier, 209, 256, 261–263, 262f
P- glycoproteins, 261
transporters, 261
Bone cancer pain, 106b
Botulinum toxin, 116, 180
Bowel dysfunction, autonomic nervous
system dysfunction, 29t
BPPV (benign paroxysmal positional
vertigo), 174–175
Brachiocephalic arteries, 227–228
Bradykinesia/akinesia, Parkinson’s disease,
205, 205f
Brain anatomy, 3–7
blood flow. See Cerebral blood flow
gyri, 4–5, 5f
internal, 7–12
axial plane, 8f
coronal sections, 8–11, 9f–10f
horizontal sections, 11–12, 12f
midsagittal section, 9f
sagittal sections, 6f, 7–8
medulla, 6
closed, 6
corticospinal tract, 6
inferior olivary nuclei, 6
open, 6
pyramids, 6
pons, 4–5
trigeminal nerve, 6
See also specific structures
sulci, 4–5, 5f
supraspinal (descending) analgesia, 97–99
surface features, 4–5, 5f
central sulcus, 4
lateral fissure of Sylvius, 4
longitudinal fissure, 4, 7–8, 9f
parieto- occipital sulcus, 4
symmetry, 14
ventricular system, 2–3, 7, 8f
CSF, 7
Brain contusions/lacerations, head injury,
249–250
INDEX
375

INDEX
Brain hemisphere, left
fine movements, 15
language, 15–16
Brain hemisphere, right
lesion studies, 22
spatial movements, 15
Brain hemisphere(s), specialization, 14–16,
14f, 16f
language centres, 14
writing, 14
Brain injury
See also specific types of injury
swelling, 250
tumours, 247f
Brainstem, 2, 6, 120
anatomy, 3–12, 121–122, 122f
ascending tracts, 122
blood supply, 126, 129f, 224
cranial nerve association, 120
dorsal view, 122–123
mediolateral plane, 122
MRI, 121–122
reticular formation. See Reticular
formation (RF)
superior view, 123f
ventrolateral system, 76
Wiegert–Pow stained sections, 121f
functions, 122t
accommodation reflex, 130
acoustic reflexes. See Auditory system
blink reflexes, 130
conduit functions, 120
cranial nerve- related functions, 119
Doll’s eye (vestibulo- ocular)
reflex, 130
gag reflex, 130
heart rate control, 128f, 128b
integrative functions, 120
jaw jerk reflex, 130
pupillary light reflex. See below
reflexes, 125t, 126
lesions, 130–132
bilateral signs, 131
compression injuries, 131–132
unilateral lateral, 130, 131t
unilateral medial, 130, 131t
pupillary light reflex, 127–130, 129t, 141
Edinger–Westphal nucleus, 127–129
Horner’s syndrome, 127–129, 128f
See also specific reflexes
Brainstem death, 129b
Broca’s area, 14
damage, 166b
cortical function examination, 167–168
speech understanding, 166b
Brodmann’s area, discriminative touch
system, 74–75
Buprenorphine, 108
opiate addiction therapy, 361–362
Bupropion, 343, 346
smoking cessation, 366
Bushy cells, auditory pathways, 163
Buspirone, 351
Butyrylcholinesterase, 51
C
C- fibres, nociceptors, 92
C1q complement receptor, Alzheimer’s
disease, 308
CA1 outputs, hippocampus LTP, 136
CA3 neurons, hippocampus LTP, 300
CAG repeats, huntingtin, 219–220
Calcarine sulcus, 141f
Calcium channels, epilepsy, 284
Calcium homeostasis, Alzheimer’s disease
β- amyloid hypothesis, 307
Calcium- channel blockers (CCBs)
migraine prevention, 115
Callosomarginal artery, 227
Callosotomy, epilepsy, 291
Caloric test, balance disorders, 175
Canal of Schlemm, 137, 137f
Cancer pain, 106b
WHO analgesic ladder, 106t, 106b
Cannabinoid receptors, 364b
Cannabis (marijuana), 363–365, 364b
cannabinoid receptors, 364
depolarization- induced suppression of
inhibition, 364
mechanism of action, 364
modulatory effects, 364, 365f
Carbamazepine
depression therapy, 346
efficacy, 288t
epilepsy treatment, 288
trigeminal neuralgia management, 116
Carbidopa, L- DOPA combination, 211–212
Cataracts, 137
Caudate nucleus, sagittal plane, 9–10
Caudate nuclei
horizontal sections, 11–12
movement, 202
Cell injury mechanisms, ischaemic stroke.
See Ischaemic stroke
Cell transplantation
Parkinson’s disease treatment, 215–216,
215f, 215t
spinal cord injury management, 85–86
Cellular neuroscience, 33–52
Central cord syndrome, 84
Central nervous system (CNS), 2–3
anatomy, 3
pain perception. See Pain
See also specific components
Central neurotransmitters, 45–46
Central pathways, vestibular system,
173–174, 174f
Central sulcus, 4
brain anatomy, 5f
Centre- surround fields, visual contrast
detection, 149, 149f
Cephalosporins, resistance, 267b
Cerebellum, 194–200
anatomy, 6f, 194–195
anterior lobe, 195
blood supply, 226–229
cerebrocerebellum. See below
deep cerebellar nuclei. See below
Cerebellum (Continued)
paramedian region, 197
posterior lobe, 195
cerebrocerebellum, 197, 198f
motor skills, 197–198
cuneocerebellar pathway, 195t
deep cerebellar nuclei, 197
dentate nucleus, 197
diseases/disorders, 198–200
anterior lobe lesions, 200
causes, 199t
genetic causes, 198–199
posterior lobe lesions, 200
trauma, 199
vermis lesions, 200
flocculonodular lobe, 197
functional organization, 197–198
midline nodulus, 197
paired flocculus, 197
vermis, 197
vestibulocerebellum, 197
input pathways, 195t
long- term depression, 301
metabotropic glutamate
receptors, 301
procedural (motor) learning, 301
microcircuitry, 195–196, 196f
basket neurones, 196
climbing fibres, 195
Golgi cells, 196
granule cells, 196
mossy fibres, 195
Purkinje cells, 196
stellate neurones, 196
movement control, 178–179, 198, 198f
feedback control, 198, 199f
feedforward control, 198, 199f
olivocerebellar pathway, 195t
pontocerebellar pathway, 195t
spinocerebellar pathway, 195, 195t
locomotor coordination, 197
vestibulocerebellar pathway input, 197
trigeminocerebellar pathway, 195t
vestibulocerebellar pathway, 195, 195t,
198f
spinocerebellar tract input, 197
Cerebral abscesses, 256–257, 269–270, 269f
Cerebral blood flow
cerebral perfusion pressure, 225
control, 225–226
autoregulation, 225
blood flow rate, 225
hypercarbia, 225
hypocarbia, 225
hypoxia, 225
vasodilating agents, 225
See also specific vessels
supply, 226–229
anterior system branches, 226–227, 228f,
231f
posterior system branches, 226–228,
228f
venous system, 228–229, 230f
functional anatomy, 229, 231t
376

Cerebral cortex
anatomy, 12
blood supply, 226–229
chandelier cells, epilepsy, 285, 287f
clinical examination. See Clinical
examination
discriminative touch system, 74–76
EEG, 278
functional anatomy, 14f
pain perception, 95b
primary areas, 12f
regions of association, 11, 11f
Cerebrocerebellum. See Cerebellum
Cerebrospinal fluid (CSF)
blockage, spinal cord syndromes, 137
circulation, 259–263
composition, 259, 259t
examination, 64–65
flow, 260f
maximum lumbar pressure, 65
normal volume, 65
production, 259–263, 259f
choroid epithelial cells, 259–260
sampling, meningitis. See Meningitis
Cerebrum, sagittal plane, 7–8
Chemical synapses, 44
Chemoreceptors, 22–23, 22t
Childhood absence epilepsy (CAE), 276t
Chloramphenicol, resistance, 267b
Chlorpromazine, 328b
schizophrenia therapy, 327
Choline acetyltransferase (CAT),
Alzheimer’s disease, 304
Cholinergic cells, reticular formation, 126
Cholinergic system, depression, 341
Cholinesterase inhibitors, Alzheimer’s
disease treatment, 308–309
Chorea, Huntington’s disease, 220
Choroid, 137, 137f
epithelial cells, CSF production, 259–260
Chronic insomnia, 352
Chronic pain, 92t
Chronic traumatic encephalopathy, 250–251
Ciliary body, 137, 137f
Ciliary process, 137
Cingulate cortex, functions, 17
Cingulate gyri, 4–5, 5f, 16
limbic system, 16
Cingulate sulcus, 4–5, 5f
Circadian rhythm, hypothalamus, 21
Circle of Willis, 226–227, 226f
Circulatory input, hypothalamus, 20
Citalopram, 343
Claustrum nucleus, sagittal plane, 9–10
Climbing fibres, cerebellum, 314
Clinical examination, 54
coordination, 60
cortical function, 61–62
apraxias, 61
Broca’s area damage, 61–62
constructional apraxia, 61
Glasgow Coma Scale, 62
graphesthesia, 61
higher mental skills, 61
Clinical examination (Continued)
parietal lobe lesions, 61
spatial awareness, 61
speech abnormalities, 61–62
stereognosis, 61
Wisconsin card- sorting test, 61
working memory, 61
cranial nerves, 56–58
CSF examination, 64–65
electrical activity, 64
gait, 60
Parkinson’s disease, 60
postural stability, 60
Romberg test, 60
mental state, 55–56
appearance, 55
behaviour, 55
confusion, 55
impaired concentration, 56
mood, 55
obsessional ruminations, 56
perceptual abnormalities, 56
speech, 55
suicidal ideation, 55
motor function, 58–60
muscle power, 59, 59t
muscle tone, 59
visual inspection, 59
neuroimaging, 62–64
patient history, 54
physical examination, 54
reflexes, 59–60
Babinski sign, 59
deep tendon reflexes, 59
hyperreflexia, 59
superficial reflexes, 59–60
See also specific cranial nerves
See also specific methods
sensory examination, 60–61
lesion site identification, 61
nociception, 60–61
temporal data, 54
Clobazam
efficacy, 288t
epilepsy treatment, 288
Clomipramine, depression and anxiety, 354.
e1
Clonazepam, epilepsy treatment, 288
Clonic seizures, 275
Clonidine, opiate addiction therapy, 361
Clozapine, schizophrenia therapy, 361
CNS. See Central nervous system (CNS)
Cocaine addiction, 356, 362–363
tolerance, 363
treatment, 363
withdrawal, 362
Cochlea, 159f, 160, 161f
Cochlear implants, 169
Cochlear nerve, 159f
afferents, 163
damage, 165–167
conduction deafness, 166–167
nerve deafness, 166–167
Codeine, 108
Cognitive behavioural therapy (CBT)
depression, 345
pain perception, 100
Cognitive function
dementia, 296
prefrontal cortex, 326b
Cognitive therapy, schizophrenia, 330
Colour blindness, 139b
Colour vision
cones, 146–147
retinal ganglion cells, 151, 151f
Complete spinal cord transection, 84
Complex cells, visual cortex, 152–153
Complex partial seizures, 282
Compression
brainstem, 131–132
spinal cord syndromes, 83
Computed tomography (CT)
clinical examination, 62
dementia, 298–299, 298f
epilepsy diagnosis, 281
Huntington’s disease, 218–219
MRI vs., 62–63
schizophrenia, 322
spinal cord, 81–82
Concentration, impaired, mental state
examination, 56
Concussion, 250–251
Conduction aphasia, lesions, 166b
Conduction deafness, 166–167
Conduit functions, brainstem, 120
Cone cells, 146–147
colour vision, 146–147
opsins, 148
spectral sensitivity, 147f
structure, 148f
Confusion
dementia vs., 297t
mental state examination, 55
Parkinson’s disease, 206
Congenital insensitivity to pain with
anhydrosis (CIPA), 91
Conjunctiva, 136–137, 137f
Constructional apraxia, cortical function
examination, 61
Contralateral lateral lemniscus, auditory
pathways, 163
Contralateral tracts, visual pathways, 140
Contrast detection. See Retina
Contre- coup’ brain damage, 249–250
Cornea, 137f
Coronal sections, brain anatomy, 8–11, 9f–11f
Coronary heart disease, nicotine addiction,
366
Corpus callosum, 5f
horizontal sections, 4–5
Corticobulbar tract, motor systems, 188
Corticolimbic circuits, schizophrenia,
322–324, 324f
Corticospinal tract (CST)
medulla, 6
motor systems, 188
Corticotrophin- releasing factor (CRF),
depression, 341
INDEX
377

INDEX
Counter- stimulation analgesia. See
Analgesia
Coup’ brain damage, 249–250
Crack. See Cocaine addiction
Cranial motor functions, reticular formation,
126
Cranial nerve I (olfactory nerve), 124t
examination, 56
Cranial nerve II (optic nerve), 124t
clinical examination, 56
Cranial nerve III (oculomotor nerve), 124t
clinical examination, 56–57
adduction defects, 56–57, 57f
eye movement, 144
Cranial nerve IV (trochlear), 124t
clinical examination, 56–57
Horner’s syndrome, 56–57, 57f
pupil dilation, 56–57
Cranial nerve IX (glossopharyngeal nerve),
124t
clinical examination, 58
Cranial nerve V (trigeminal nerve), 124t
clinical examination, 57
touch/pin- prick testing, 57
Cranial nerve VI (abducens nerve), 124t
clinical examination, 56–57
Cranial nerve VII (facial nerve), 124t
clinical examination, 57–58, 58f
Cranial nerve VIII (auditory and vestibular
nerve), 124t
clinical examination, 58
nystagmus, 58
Rinne’s test, 58
vertigo, 58
Weber’s test, 58
Cranial nerve X (vagus nerve), 124t
clinical examination, 58
stimulation, depression therapy, 345
Cranial nerve XI (accessory nerve), 124t
clinical examination, 58
Cranial nerve XII (hypoglossal nerve), 124t
clinical examination, 58
Cranial nerve(s), 24, 120, 124t
anatomy, 120
brainstem association, 120–123
classification, 120t
clinical examination, 56–58
functions, 120
spinal nerves vs., 123b
CREB (cyclic AMP response- element
binding protein), addiction, 359
Creutzfeldt–Jakob disease (CJD), 257, 314
prion protein, 314
Crista, vestibular system, 170f
Crossed extensor reflexes, polysynaptic
reflexes, 186, 186f
CT. See Computed tomography (CT)
Cuneocerebellar pathway, cerebellum,
195t
Curare, 180–181
Cutaneous nociceptors, 93
Cutaneous referred areas, pain, 96f
Cyclic AMP response- element- binding
protein (CREB), addiction, 359
Cyclo- oxygenase (COX) inhibition,
nonsteroidal anti- inflammatory
drugs, 110
Cytoskeleton, neurones, 35
Cytotoxic brain swelling, head injury, 244b
D
DAI (diffuse axonal injury), 250
Daytime sedation, benzodiazepines, 353
DCN (dorsal cochlear nucleus), 163
Deafness, 158
causes, 167–168
gradual deterioration, 168
hereditary disease, 168
tumours, 168f
conduction, 166–167
infections, 167–168
perinatal, 168
prenatal, 167–168
nerve, 166–167
ototoxic agents, 168
treatment, 168–169
cochlear implants, 169
hearing aids, 169
tympanostomy tubes (grommets), 169
Decerebrate rigidity, upper motor neurones,
192b
Declarative learning, 299
Decorticate rigidity, upper motor neurones,
192b
Decreased pain threshold, peripheral
sensitization, 101
Deep brain stimulation (DBS), depression
therapy, 345
Deep cerebellar nuclei. See Cerebellum
Deep cerebral veins, 228–229
Deep tendon reflexes, 183t
examination, 59
Déjerine’s syndrome, 131
Delirium tremens, 368b
Delta (δ) opioid receptors, 107, 108t
Delta rhythm, EEG, 278–280
Delusions, solvent abuse, 371
Dementia, 296
case history, 296b
causes, 296–299, 297t
confusion vs., 297t
definition, 296
depression, 314–315
diagnosis, 296–299
blood tests, 298–299
cognitive function, 296
CT, 269f, 298–299
Mini Mental State Examination,
297–298, 298t
MRI, 298–299
psychological testing, 297
management, 314–315
neurobiology, 322–327
Parkinson’s disease, 216–218
Dementia with Lewy bodies, 312–313
Demyelinating disease, spinal cord injury, 80t
Demyelinating diseases, 39b
Dendrites, neurones, 34
Dentate gyrus, hippocampus LTP, 285
Dentate nucleus, cerebellum, 5–6
Depolarization- induced suppression of
inhibition, cannabis, 364
Depression
age of onset, 338–339
agitated, 334
brain structures, 339–340
case history, 335b, 348
DSM- IV, 335t
epidemiology, 335–339
neurobiology, 339–341
neurochemistry, 340–341
prefrontal cortex hypometabolism, 339f
psychotherapy, 345
ratings, 335–338
Hamilton Rating Scale, 336b–338b
resistance to, 346–347
retarded, 334
See also Antidepressant drugs specific
drugs
sleep disorders, 351
somatic symptoms, 334
suicide risk, 347
treatment, 349–351
electroconvulsive therapy, 344–345
pharmacological management, 341–343
Dermatomes, 24–25, 26f
functions, 27t
Descending somatosensory pathways,
78–79, 79f, 79t
Desynchronicity, EEG, 278–280
Detached retina, 146
Diagnostic and Statistical Manual of Mental
Disorders (DSM- IV)
depression, 335t
mood disorders, 335t
schizophrenia, 320–321
Diamorphine (heroin), 108, 361
Diazepam, 350–351
pharmacokinetics, 350t
status epilepticus, 292
Diencephalon
anatomy, 18
blood supply, 226
epithalamus, 18
Dietary treatment, epilepsy, 291–292
Diffuse axonal injury (DAI), 250
Diffuse nuclei, thalamus, 18–19
Dihydroergotamine, migraine treatment, 113
Direct pathway, basal ganglia, 203
Direct postsynaptic inhibition, supraspinal
(descending) analgesia, 98
Direct presynaptic inhibition, supraspinal
(descending) analgesia, 98
Discriminative touch system
somatosensory pathways, 79
spinal cord. See Spinal cord
Disorientation, Parkinson’s disease, 206
Disulfiram, alcohol dependence treatment,
367–368
Diuretics, stroke prevention, 241–242
378
Соседние файлы в папке Библиотека им академика М.И. Перельмана
